

In the Claims:

Claims 1-26 (Cancelled)

27. (Previously Amended): An isolated polypeptide comprising a member selected from the group consisting of

- (a) an amino acid sequence matching SEQ ID NO:2 and
- (b) an immunogenic polypeptide comprising a fragment sequence of at least 15 amino acids that matches an aligned contiguous segment of SEQ ID NO:2,

wherein the isolated polypeptide, when administered to a subject in a suitable composition which can include an adjuvant, or a suitable carrier coupled to the polypeptide, induces an antibody or T-cell mediated immune response to a polypeptide having the sequence of SEQ ID NO:2.

28. (Cancelled)

29. (Previously Added): The isolated polypeptide of claim 27, wherein the polypeptide is according to (a).

Claims 30-31 (Cancelled)

32. (Previously Added): The isolated polypeptide of claim 27, wherein the polypeptide is according to (b).

33. (Cancelled)


34. (Previously Added): The isolated polypeptide of claim 27, wherein the immunogenic fragment of (b) comprises at least 20 amino acids.

35. (Previously Added): The isolated polypeptide of claim 27, wherein the isolated polypeptide consists of SEQ ID NO:2.

Claims 36-37 (Cancelled)

38. (Previously Amended): A fusion protein comprising the isolated polypeptide of Claim 27.

Claims 39-42 (Cancelled)

 43. (Currently Amended): An immunogenic composition ~~compound~~ comprising the polypeptide of Claim 27 and a pharmaceutically acceptable carrier.

44. (Previously Amended): The immunogenic composition of Claim 43, further comprising at least one additional *Moraxella catarrhalis* antigen.

Claims 45-49 (Cancelled)
